These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1106 related articles for article (PubMed ID: 3742604)

  • 1. In vivo cytotoxic responses induced by allogeneic normal and neoplastic cells in mice: relative lack of immunogenicity of B16 melanoma cells.
    Ashley MP; Kotlarski I
    Cell Immunol; 1986 Aug; 101(1):156-67. PubMed ID: 3742604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early development of CD8-negative and CD8-positive MHC-unrestricted cytotoxic cells induced by alloantigen inoculation in mice.
    Nishi Y; Hosokawa T; Aoike A; Kawai K; Kamahora T
    Microbiol Immunol; 1990; 34(9):775-85. PubMed ID: 2126592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defects in tumor cell immunogenicity: lymphokine signals in in vitro cytolytic responses to tumor alloantigens.
    Ashley MP; Kotlarski I; Vari F
    Cell Immunol; 1987 Apr; 106(1):151-62. PubMed ID: 3568144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated soluble fractions from the murine B16 melanoma induce primary in vitro syngeneic antitumor responses.
    Klein BY; Frenkel S; Naor D
    Cancer Immunol Immunother; 1984; 18(3):195-202. PubMed ID: 6239687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo and in vitro analyses of the immunogenicity of B16 melanoma cells.
    Heath W; Boyle W
    Aust J Exp Biol Med Sci; 1985 Apr; 63 ( Pt 2)():163-75. PubMed ID: 3876093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of donor lymphoreticular cells in the rejection of B16 melanoma by allogeneic mice.
    Ashman LK; Goh DH; Kotlarski I
    Aust J Exp Biol Med Sci; 1980 Apr; 58(2):159-66. PubMed ID: 7436875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired H-2 expression in B16 melanoma variants.
    Nanni P; Colombo MP; De Giovanni C; Lollini PL; Nicoletti G; Parmiani G; Prodi G
    J Immunogenet; 1983 Oct; 10(5):361-70. PubMed ID: 6644070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes.
    Fidler IJ; Bucana C
    Cancer Res; 1977 Nov; 37(11):3945-56. PubMed ID: 908034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo reexpression of H-2 antigens in B16 melanoma cells.
    Lollini PL; Colombo MP; De Giovanni C; Nicoletti G; Parmiani G; Prodi G; Nanni P
    Exp Clin Immunogenet; 1985; 2(1):14-23. PubMed ID: 3939971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth and metastasis in allogeneic hosts. Lack of H-2-negative or somatic hybrid variant selection.
    De Giovanni C; Lollini PL; Nicoletti G; Del Re B; Scotlandi K; Prodi G; Nanni P
    Exp Clin Immunogenet; 1987; 4(3):153-62. PubMed ID: 3273420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma.
    Celik C; Lewis DA; Goldrosen MH
    Cancer Res; 1983 Aug; 43(8):3507-10. PubMed ID: 6861123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
    Stackpole CW; Demsey A
    Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma.
    Kim TS; Russell SJ; Collins MK; Cohen EP
    Int J Cancer; 1993 Nov; 55(5):865-72. PubMed ID: 8244584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo H-2K and H-2D antigen expression in two allogeneic mouse tumours of low immunogenicity.
    Ashley MP; Kotlarski I
    Immunol Cell Biol; 1987 Aug; 65 ( Pt 4)():323-8. PubMed ID: 3679289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
    Gold JE; Osband ME
    Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in cytotoxic effects of activated murine peritoneal macrophages and J774 monocytic cells on metastatic variants of B16 melanoma.
    Miner KM; Klostergaard J; Granger GA; Nicolson GL
    J Natl Cancer Inst; 1983 Apr; 70(4):717-24. PubMed ID: 6339778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cell and host properties affecting the implantation and survival of blood-borne metastatic variants of B16 melanoma.
    Fidler IJ; Nicolson GL
    Isr J Med Sci; 1978 Jan; 14(1):38-50. PubMed ID: 632082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
    Dezfouli S; Hatzinisiriou I; Ralph SJ
    Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and cross-protection among B16 melanoma variants with differing proclivities to metastasize.
    Harte PJ; Steele G; Munroe AE; Rayner AA; Wang BS; Wilson RE; Mannick JA
    J Surg Oncol; 1981; 18(4):381-8. PubMed ID: 7321567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.